Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japanese Pharmas Need To Get More Global

This article was originally published in PharmAsia News

Executive Summary

Japanese pharmaceutical companies need to have a more global reach if they intend to be major players in an increasingly international biotech and pharma market, according to Berkeley, Calif.-based Plexxikon CEO Peter Hirth

You may also be interested in...

Roche Adds To Oncology Lexicon With BRAF Kinase Deal

Plexxikon’s PLX-4032 could eventually compete against biologics in the colorectal cancer market.

U.S./Japan Free Trade Agreement Would Encourage Pharma Innovation, Lilly CEO Says

CEO Taurel argues in favor of an open market that would ease Japan-specific clinical trial requirements.

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts